OrthoPediatrics Corp. (NASDAQ:KIDS) Given Average Rating of “Buy” by Brokerages

Shares of OrthoPediatrics Corp. (NASDAQ:KIDSGet Rating) have earned an average rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $59.83.

Several equities analysts have weighed in on KIDS shares. Truist Financial dropped their price target on OrthoPediatrics to $51.00 in a research report on Friday, July 22nd. BTIG Research dropped their price target on OrthoPediatrics from $65.00 to $61.00 and set a “buy” rating for the company in a research report on Monday, July 18th. Stifel Nicolaus dropped their price target on OrthoPediatrics from $57.00 to $50.00 in a research report on Monday, July 18th. Piper Sandler dropped their price target on OrthoPediatrics from $80.00 to $55.00 in a research report on Thursday, May 5th. Finally, TheStreet downgraded OrthoPediatrics from a “c” rating to a “d+” rating in a research report on Thursday, May 5th.

Insider Transactions at OrthoPediatrics

In other OrthoPediatrics news, Director Harold Ruf acquired 1,235 shares of the firm’s stock in a transaction dated Thursday, June 16th. The shares were acquired at an average price of $39.45 per share, for a total transaction of $48,720.75. Following the completion of the acquisition, the director now directly owns 13,824 shares of the company’s stock, valued at $545,356.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 29.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brown Advisory Inc. raised its position in OrthoPediatrics by 25.2% in the second quarter. Brown Advisory Inc. now owns 1,503,287 shares of the company’s stock valued at $64,961,000 after purchasing an additional 302,186 shares during the period. Riverbridge Partners LLC raised its position in OrthoPediatrics by 0.3% in the second quarter. Riverbridge Partners LLC now owns 1,157,148 shares of the company’s stock valued at $49,931,000 after purchasing an additional 4,002 shares during the period. Wasatch Advisors Inc. raised its position in OrthoPediatrics by 0.9% in the fourth quarter. Wasatch Advisors Inc. now owns 499,437 shares of the company’s stock valued at $29,896,000 after purchasing an additional 4,503 shares during the period. Invesco Ltd. raised its position in OrthoPediatrics by 9.3% in the first quarter. Invesco Ltd. now owns 455,486 shares of the company’s stock valued at $24,593,000 after purchasing an additional 38,638 shares during the period. Finally, Summit Partners Public Asset Management LLC raised its position in OrthoPediatrics by 11.5% in the fourth quarter. Summit Partners Public Asset Management LLC now owns 436,123 shares of the company’s stock valued at $26,106,000 after purchasing an additional 44,973 shares during the period. Institutional investors and hedge funds own 71.51% of the company’s stock.

OrthoPediatrics Price Performance

NASDAQ KIDS opened at $49.20 on Thursday. OrthoPediatrics has a 1-year low of $36.71 and a 1-year high of $73.91. The company has a market capitalization of $995.32 million, a P/E ratio of -63.90 and a beta of 0.88. The business has a 50 day moving average price of $44.29 and a 200 day moving average price of $47.36.

OrthoPediatrics (NASDAQ:KIDSGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). The firm had revenue of $23.42 million during the quarter, compared to the consensus estimate of $22.70 million. OrthoPediatrics had a negative return on equity of 7.04% and a negative net margin of 14.98%. On average, research analysts expect that OrthoPediatrics will post -0.8 earnings per share for the current fiscal year.

OrthoPediatrics Company Profile

(Get Rating)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

See Also

Analyst Recommendations for OrthoPediatrics (NASDAQ:KIDS)

Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.